Updated on 15 January 2013
NovAliX and Kyowa Hakko Kirin to co-develop novel drug candidates against protein-protein interaction targets
Singapore: France-based biopharma company NovAliX entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin of Japan. According to the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Mr Stephan Jenn, president, NovAliX, said that, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."